Pomerantz LLP has filed a class action lawsuit against Helen of Troy Limited following significant declines in the company's earnings and stock price. The lawsuit alleges securities fraud and unlawful business practices after Helen of Troy reported a 49% drop in earnings per share in Q1 2025, an 11% sales decline and $414.4 million goodwill impairment in Q1 2026, and further sales and earnings declines in Q2 2026. Investors who suffered losses during the class period are urged to join the lawsuit by August 3, 2026. This legal action highlights concerns over the company's financial health and management disclosures.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
